Dibenzofuran
| Associated High Confidence AOPs |
|---|
Associated AOPs with Level of Relevance 1
| AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
|---|---|---|---|---|---|---|
| AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive System Disease; Cancer | - | 0.17 | KE:111 | Agonism, Estrogen receptor |
| AOP:131 | Aryl hydrocarbon receptor activation leading to uroporphyria | Inherited Metabolic Disorder | WPHA/WNT Endorsed | 0.17 | KE:850 | Induction, CYP1A2/CYP1A5 |
| AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive System Disease; Cancer | - | 0.14 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.11 | KE:850 | Induction, CYP1A2/CYP1A5 |
| AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.12 | KE:748 | Increased, Estrogen receptor (ER) activity |
Associated AOPs with Level of Relevance 2
| AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
|---|---|---|---|---|---|---|
| AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | 0.33 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | 0.2 | KE:1065 | Activation, estrogen receptor alpha |
Associated AOPs with Level of Relevance 3
| AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
|---|---|---|---|---|---|---|
| AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive System Disease | - | 0.12 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired Metabolic Disease | - | 0.1 | KE:2126 | Estrogen receptor alpha inactivation |
| AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited Metabolic Disorder; Disease Of Metabolism | - | 0.12 | KE:2126 | Estrogen receptor alpha inactivation |
| AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive System Disease; Cancer | Under Review | 0.17 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.17 | KE:111 | Agonism, Estrogen receptor |
| AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.2 | KE:111 | Agonism, Estrogen receptor |
No associated AOPs with Level of Relevance 5
DISCLAIMER
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.